Complement 3 Glomerulopathy (C3G) Overview

Some kidney diseases arrive like a loud thunderstorm. Others sneak in like a dripping faucet you keep meaning to fix. Complement 3 glomerulopathy, usually shortened to C3G, tends to fall into the second category. It is rare, complicated, and easy to miss at first. A person may notice foamy urine, swelling in the ankles, fatigue that feels heavier than ordinary tiredness, or lab results that suddenly stop looking friendly. Then comes the plot twist: the real trouble is tied to the complement system, a part of the immune system that is supposed to protect the body, not pick a fight with the kidneys.

This overview explains what C3G is, why it happens, how it is diagnosed, what treatment may look like, and what living with it often feels like. The goal is simple: make a rare disease easier to understand without turning the explanation into a medical crossword puzzle.

What Is Complement 3 Glomerulopathy?

C3G is a rare kidney disease in which abnormal activation of the complement system leads to damage in the glomeruli, the tiny filtering units inside the kidneys. The “C3” refers to complement component 3, a key protein involved in this immune pathway. The “G” stands for glomerulopathy, which basically means injury to the glomeruli. When those filters are damaged, the kidneys begin to leak blood and protein into the urine and may slowly lose their ability to remove waste and extra fluid from the body.

Although C3G is ultra-rare, it is serious. It can affect children, teens, and adults, and it is often diagnosed in younger people. Experts generally group it into two main forms:

1. Dense Deposit Disease (DDD)

This subtype is identified by dense deposits seen within the glomerular basement membrane under electron microscopy. It has the same broad disease family name, but it has its own distinct appearance under the microscope.

2. C3 Glomerulonephritis (C3GN)

This form also shows dominant C3 deposits, but the pattern of deposits and inflammation looks different from DDD. Clinically, both conditions are usually discussed under the umbrella term C3 glomerulopathy.

That microscopic difference matters because it helps confirm the diagnosis, even though the symptoms and real-life impact can overlap quite a bit.

How C3G Damages the Kidneys

To understand C3G, it helps to picture the complement system as a home security system. In a healthy body, it turns on when needed, handles a threat, and settles back down. In C3G, the system can become overactive or poorly regulated. Instead of being precise, it behaves like an alarm that will not stop blaring and starts wrecking the furniture.

That overactivity causes fragments of C3 to deposit in the kidneys. Once there, they trigger inflammation and scarring. Over time, this can reduce kidney function, increase protein loss in the urine, raise blood pressure, and in some cases lead to chronic kidney disease or kidney failure.

The disease may be linked to:

• Genetic variants in complement-related genes
• Autoantibodies that disrupt the normal regulation of the complement pathway
• Acquired immune abnormalities that keep the alternative complement pathway switched on
• Sometimes a trigger, such as infection or another immune-related issue, although not every case has a clear starting point

That last point matters. Many patients spend too much time wondering what they “did wrong.” In most cases, the honest answer is: probably nothing. C3G is not caused by laziness, bad luck at the salad bar, or one reckless weekend. It is a biologically complex disease.

How Common Is C3G?

C3G is considered a rare disease. Estimates often place it at roughly 2 to 3 cases per million people. In the United States, that means many clinicians will go years without seeing more than a few cases, if any. That rarity is one reason diagnosis can take time and why referral to a nephrologist familiar with glomerular disease is often important.

Because it is so uncommon, many patients and families hear the diagnosis and immediately ask two very reasonable questions: “What is that?” and “Why have I never heard of it?” Both are fair. Rare diseases tend to stay out of the spotlight until they land in someone’s lab report.

Signs and Symptoms of C3G

C3G symptoms can range from subtle to dramatic. Some people are diagnosed after routine urine testing. Others feel clearly unwell. Common signs and symptoms include:

• Proteinuria, or high levels of protein in the urine
• Hematuria, or blood in the urine, which may be visible or detected only under a microscope
• Foamy urine
• Swelling in the feet, ankles, legs, hands, or around the eyes
• Fatigue and reduced concentration
• High blood pressure
• Reduced kidney function, shown by rising creatinine or falling eGFR
• Dark urine or less urine than usual

Some patients also develop symptoms outside the kidneys. These may include drusen in the eyes, gout, recurrent infections, or unusual fat distribution in certain cases. Not everyone gets these extra features, but they are part of the broader C3G picture.

For example, one patient may first notice puffy eyelids in the morning and think it is just lack of sleep. Another may be a teenager whose sports performance drops because of fatigue. Someone else may feel perfectly normal until a urine test shows heavy protein loss. Same disease, very different entrance music.

How Doctors Diagnose C3G

Diagnosing C3G takes more than one test. A doctor may first suspect a kidney problem after finding protein or blood in the urine, but the definitive diagnosis requires a kidney biopsy.

Urine and Blood Tests

Before biopsy, doctors often use routine kidney testing to build the case. That may include:

• Urinalysis to look for blood and protein
• UACR or UPCR to measure how much protein is leaking into the urine
• Serum creatinine and eGFR to estimate kidney function
• Complement testing, including C3 levels
• Additional immune and lab studies to rule out other conditions

Kidney Biopsy

A kidney biopsy is the key test. Tissue from the kidney is examined using special microscopy techniques. In C3G, the hallmark finding is dominant C3 staining in the glomeruli. Electron microscopy then helps determine whether the pattern fits DDD or C3GN.

Genetic and Complement Pathway Testing

Some patients also undergo genetic testing or more specialized complement pathway studies. These tests can help identify inherited variants or acquired abnormalities, support family counseling, and sometimes guide treatment decisions. They are especially helpful when the history suggests a complement-mediated disease pattern.

In short, C3G diagnosis is not based on one dramatic clue. It is more like assembling a puzzle from urine findings, bloodwork, pathology, and complement testing.

Treatment Options for C3G

There is no one-size-fits-all treatment plan for C3G. Care is individualized based on age, disease severity, proteinuria, kidney function, biopsy findings, and whether the patient has native-kidney disease or disease recurrence after transplant.

Supportive Kidney Care

Even when the disease mechanism is complex, the basics still matter. Supportive treatment may include:

• Controlling blood pressure
• Using ACE inhibitors or ARBs to help reduce proteinuria
• Managing swelling with diet changes and, when appropriate, medicines
• Addressing cholesterol, gout, or other complications
• Monitoring kidney function regularly

These steps may sound boring compared with high-tech immunology, but boring is underrated in nephrology. Sometimes steady blood pressure control does a lot of quiet, important work.

Immunosuppressive Therapy

In selected cases, clinicians may use immunosuppressive medicines, especially when the overall clinical picture suggests they might help. Response can be variable, which is one reason C3G has historically been such a frustrating disease to manage.

Targeted Complement Inhibitors

The treatment landscape has changed in an important way. Newer therapies that target complement activity have brought real momentum to C3G care.

As of 2026 in the United States:

• Fabhalta (iptacopan) is FDA-approved for adults with C3G to reduce proteinuria.
• Empaveli (pegcetacoplan) is FDA-approved for adults and pediatric patients age 12 and older with C3G to reduce proteinuria.

These approvals are a big deal in a disease area that went a long time with limited targeted options. They do not mean every patient will respond the same way, and they do not erase the need for close follow-up, but they represent a genuine shift from purely supportive care toward therapy that addresses the complement pathway itself.

Important Safety Considerations

Complement inhibitors can increase the risk of serious infections caused by encapsulated bacteria. That is why vaccination and infection-prevention planning are important before starting therapy. These drugs are used with specific safety programs and monitoring requirements. In plain English: they can be valuable, but they are not “grab a prescription and wing it” medications.

Dialysis and Kidney Transplant

If C3G progresses to kidney failure, dialysis or transplant may become necessary. Unfortunately, C3G can recur after kidney transplant, which is one reason long-term planning and specialized nephrology follow-up matter so much. Transplant can still be life-changing and appropriate, but recurrence risk is part of the conversation.

What Is the Outlook for People With C3G?

C3G is highly variable. Some people have relatively slow disease progression. Others worsen much faster. Spontaneous remission is uncommon, and a substantial portion of patients may progress to kidney failure within about a decade of diagnosis.

That said, prognosis is not destiny. Earlier recognition, better proteinuria monitoring, improved understanding of the complement system, and the arrival of targeted therapies are changing the conversation. “Rare and serious” still applies, but “nothing can be done” is no longer the right summary.

Ongoing monitoring usually includes kidney function tests, urine protein measurements, blood pressure checks, and clinical review by a nephrologist. Some patients may also need periodic eye evaluation, especially if there is concern for drusen or related changes.

Living With C3G Day to Day

Medical definitions only tell part of the story. The daily reality of C3G often includes logistics, uncertainty, and a lot of mental math. How much energy do I have today? What did the latest labs show? Is this swelling worse or just annoying? Can I plan a trip, a school semester, a pregnancy, a new job, or should I wait for the next appointment?

Practical strategies that often help include:

• Keeping a record of lab values, medications, and symptoms
• Seeing a nephrologist experienced in glomerular disease when possible
• Following a kidney-friendly nutrition plan tailored by the care team
• Taking swelling, fatigue, and blood pressure changes seriously
• Asking about genetics or complement testing when appropriate
• Looking for emotional support, not just medical support

That last point deserves emphasis. Rare disease can be isolating. Patients often spend months or years explaining their condition to people who have never heard of it, including, sometimes, clinicians outside nephrology. Support groups, kidney organizations, and informed caregivers can make a real difference.

Experiences Related to Complement 3 Glomerulopathy (C3G) Overview

Living with C3G is often described as a long stretch of uncertainty interrupted by moments of intense clarity. One week, a person may feel almost normal. The next, they may be dealing with swelling, fatigue, a scary lab result, or another specialist visit. Many patients say the hardest part is not always pain. It is unpredictability. You cannot “out-organize” a disease that sometimes changes course before breakfast.

Fatigue comes up again and again in conversations about C3G. Not everyday tiredness. Not “I stayed up too late watching one more episode” tiredness. The kind of fatigue that can make school, work, exercise, or basic household tasks feel much heavier than they should. Some people describe brain fog along with low energy. They know what they want to do, but their body and attention span have other ideas.

Swelling can be another major burden. It is not just a cosmetic issue. It can make walking uncomfortable, shoes impossible, and ordinary routines oddly difficult. A person may look fine to everyone else and still feel miserable. That mismatch between how someone appears and how they feel can be frustrating. Rare disease patients become experts at hearing, “But you look great,” on days when they absolutely do not feel great.

Families often carry their own version of the burden. Parents may juggle school schedules, labs, insurance calls, biopsy anxiety, and the emotional weight of watching a child live with a disease they cannot simply fix. Partners and caregivers may become unofficial care coordinators, medication managers, and late-night search engines. It is a lot. Even when love is abundant, the stress can be too.

Then there is the emotional layer. Many people with C3G describe worry about the future: Will my kidney function stay stable? Will I need dialysis? If I get a transplant, will the disease come back? Those are not small questions. They sit in the background of daily life, influencing choices about work, family planning, travel, finances, and mental health.

At the same time, patients also describe resilience. They learn lab terms they never wanted to know. They become sharp observers of their own symptoms. They ask better questions at appointments. They find community. They celebrate stable test results like championship trophies, and honestly, that makes sense. In rare kidney disease, a good lab day deserves confetti, or at least very enthusiastic coffee.

New treatment options have also changed the emotional tone for many patients. Hope feels different when it is attached to real therapies rather than vague promises. That does not erase the challenges of C3G, but it can soften the feeling of being stuck with only watchful waiting. For many families, that shift matters deeply.

So, beyond the biopsy slides, complement pathways, and medication names, the experience of C3G is really about adaptation. It is about learning how to keep living while the medical story is still unfolding. That is not easy. But it is real, and it is part of any honest overview of C3G.

Conclusion

Complement 3 glomerulopathy is rare, complex, and potentially serious, but it is no longer a disease discussed only in the language of confusion and limited options. C3G begins with complement dysregulation, damages the glomeruli, and may lead to proteinuria, hematuria, swelling, fatigue, and declining kidney function. Diagnosis depends on a careful workup and a kidney biopsy, while treatment now includes both supportive kidney care and targeted complement-directed therapies.

The most important takeaway is this: C3G is complicated, but it is not hopeless. With experienced nephrology care, regular monitoring, and a treatment plan tailored to the individual, patients and families have more knowledge and more options than they did even a few years ago. In rare disease terms, that is not a small update. That is progress.

Note: This article is for educational purposes only and does not replace professional medical advice, diagnosis, or treatment.